液体活检用于筛选肌层浸润性膀胱癌围手术期化疗患者:系统综述
该系统综述检索PubMed并筛选22篇文献,评估循环肿瘤细胞(CTC)和游离DNA(cfDNA)在肌层浸润性膀胱癌(MIBC)围手术期化疗选择中的价值。CellSearch检测的CTC是不良生存的稳健标志物,cfDNA预后价值不一,液体活检有望指导化疗决策但需前瞻性临床适用性研究。
要点
- CellSearch检测的CTC是MIBC根治性膀胱切除术前不良无复发生存和总生存的稳健标志物。
- cfDNA在MIBC患者血液中可检测到,但其预后价值研究结果不一致。
- 液体活检有望指导MIBC围手术期化疗选择,但亟需前瞻性临床适用性研究。
核心结论
- 液体活检在筛选MIBC患者进行围手术期化疗方面有前景,但亟需前瞻性研究验证真实临床适用性以指导治疗决策。
研究设计与样本
- 系统综述,遵循PRISMA,检索PubMed数据库,共筛选215篇论文并纳入22篇评估CTC和cfDNA的临床价值。
主要发现
- 根治性膀胱切除术前通过CellSearch技术检测到一个或多个CTC是不良无复发生存和总生存的稳健标志物。
- cfDNA存在于MIBC患者血液中,但其预后价值的研究结果不一。
- 基于cfDNA的成功方法可能需涵盖多个基因并使用下一代测序,因为MIBC中热点体细胞突变通常较少。
临床怎么用
- CTC检测可能有助于识别根治性膀胱切除术前预后不良的MIBC患者,但能否据此决定是否省略新辅助化疗(NAC)仍在研究中。
- cfDNA用于治疗决策尚不成熟,需进一步标准化和前瞻性验证。
局限性
- 纳入研究多为原理验证性研究,缺乏前瞻性临床适用性研究来验证液体活检指导治疗决策的真实价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Neoadjuvant chemotherapy (NAC) is considered the standard treatment for muscle-invasive bladder cancer (MIBC). However, its overall survival benefit is limited and toxicity is significant; hence, NAC has not been adopted universally. OBJECTIVE: To systematically evaluate whether biomarkers can guide the administration of perioperative chemotherapy in MIBC patients. EVIDENCE ACQUISITION: A systematic search of the PubMed database was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA). In total, 215 papers were screened and 22 were selected to assess the potential clinical value of circulating tumor cells (CTCs) and cell-free DNA (cfDNA) in selecting MIBC patients for perioperative chemotherapy. EVIDENCE SYNTHESIS: We found that the presence of one or more CTCs before radical cystectomy, as determined by the CellSearch technique, is a robust marker for poor recurrence-free and overall survival. Consequently, whether NAC can be withheld in patients without the presence of CTCs is a subject of ongoing investigation. Studies investigating various approaches to detect cfDNA showed that cfDNA is present in the blood of MIBC patients, but varying results on its prognostic value have been reported. Successful cfDNA-based approaches are likely to encompass at least a multitude of genes using next-generation sequencing, as there are generally few hotspot somatic mutations in MIBC. CONCLUSIONS: Liquid biopsies hold promise in selecting MIBC patients for perioperative chemotherapy, but instead of more proof-of-principle studies, prospective studies investigating true clinical applicability for treatment decision making are urgently needed. PATIENT SUMMARY: Liquid biopsies appear to be a promising tool to guide the administration of chemotherapy in patients with muscle-invasive bladder cancer; however, the optimal way to implement these remains to be determined.
引用
- de Kruijff IE, Beije N, Martens JWM, et al. Liquid Biopsies to Select Patients for Perioperative Chemotherapy in Muscle-invasive Bladder Cancer: A Systematic Review. Eur Urol Oncol. 2020. PMID: 32059957. doi:10.1016/j.euo.2020.01.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。